nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—CYP3A4—type 2 diabetes mellitus	0.135	1	CbGaD
Ruxolitinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0163	0.152	CbGbCtD
Ruxolitinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0146	0.136	CbGbCtD
Ruxolitinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0133	0.124	CbGbCtD
Ruxolitinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0116	0.109	CbGbCtD
Ruxolitinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0105	0.0982	CbGbCtD
Ruxolitinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00797	0.0744	CbGbCtD
Ruxolitinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00764	0.0713	CbGbCtD
Ruxolitinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00764	0.0713	CbGbCtD
Ruxolitinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00723	0.0675	CbGbCtD
Ruxolitinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00539	0.0503	CbGbCtD
Ruxolitinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00493	0.046	CbGbCtD
Ruxolitinib—RET—autonomic nervous system—type 2 diabetes mellitus	0.00486	0.0263	CbGeAlD
Ruxolitinib—GRK7—retina—type 2 diabetes mellitus	0.00408	0.0221	CbGeAlD
Ruxolitinib—BMPR2—artery—type 2 diabetes mellitus	0.00362	0.0196	CbGeAlD
Ruxolitinib—CAMK2G—nerve—type 2 diabetes mellitus	0.00321	0.0174	CbGeAlD
Ruxolitinib—MAP3K3—peripheral nervous system—type 2 diabetes mellitus	0.00319	0.0173	CbGeAlD
Ruxolitinib—LRRK2—nerve—type 2 diabetes mellitus	0.00318	0.0172	CbGeAlD
Ruxolitinib—GRK1—retina—type 2 diabetes mellitus	0.00295	0.016	CbGeAlD
Ruxolitinib—PLK3—islet of Langerhans—type 2 diabetes mellitus	0.00271	0.0147	CbGeAlD
Ruxolitinib—PRKG2—cardiovascular system—type 2 diabetes mellitus	0.00262	0.0142	CbGeAlD
Ruxolitinib—PRKG2—kidney—type 2 diabetes mellitus	0.00256	0.0139	CbGeAlD
Ruxolitinib—PLK1—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.00244	1	CbGdCrCtD
Ruxolitinib—RPS6KA6—cardiovascular system—type 2 diabetes mellitus	0.00235	0.0127	CbGeAlD
Ruxolitinib—PRKCE—adipose tissue—type 2 diabetes mellitus	0.00216	0.0117	CbGeAlD
Ruxolitinib—JAK1—islet of Langerhans—type 2 diabetes mellitus	0.00208	0.0113	CbGeAlD
Ruxolitinib—PLK3—cardiovascular system—type 2 diabetes mellitus	0.00196	0.0106	CbGeAlD
Ruxolitinib—STK16—islet of Langerhans—type 2 diabetes mellitus	0.00195	0.0106	CbGeAlD
Ruxolitinib—PLK3—pancreas—type 2 diabetes mellitus	0.0019	0.0103	CbGeAlD
Ruxolitinib—DAPK3—islet of Langerhans—type 2 diabetes mellitus	0.00186	0.0101	CbGeAlD
Ruxolitinib—CAMK1—cortex of kidney—type 2 diabetes mellitus	0.00175	0.00946	CbGeAlD
Ruxolitinib—CAMK1D—retina—type 2 diabetes mellitus	0.00173	0.00939	CbGeAlD
Ruxolitinib—PLK3—adipose tissue—type 2 diabetes mellitus	0.00173	0.00936	CbGeAlD
Ruxolitinib—JAK1—nephron tubule—type 2 diabetes mellitus	0.00167	0.00906	CbGeAlD
Ruxolitinib—NUAK2—islet of Langerhans—type 2 diabetes mellitus	0.00166	0.009	CbGeAlD
Ruxolitinib—PRKG2—liver—type 2 diabetes mellitus	0.00162	0.00876	CbGeAlD
Ruxolitinib—CAMK1—adipose tissue—type 2 diabetes mellitus	0.00162	0.00875	CbGeAlD
Ruxolitinib—MARK2—adipose tissue—type 2 diabetes mellitus	0.00157	0.00849	CbGeAlD
Ruxolitinib—HIPK2—nephron tubule—type 2 diabetes mellitus	0.00156	0.00846	CbGeAlD
Ruxolitinib—ROCK1—retina—type 2 diabetes mellitus	0.00153	0.00829	CbGeAlD
Ruxolitinib—PRKCE—liver—type 2 diabetes mellitus	0.00151	0.00818	CbGeAlD
Ruxolitinib—JAK1—cardiovascular system—type 2 diabetes mellitus	0.0015	0.00814	CbGeAlD
Ruxolitinib—JAK1—kidney—type 2 diabetes mellitus	0.00147	0.00796	CbGeAlD
Ruxolitinib—JAK1—pancreas—type 2 diabetes mellitus	0.00146	0.00791	CbGeAlD
Ruxolitinib—RPS6KA6—liver—type 2 diabetes mellitus	0.00145	0.00786	CbGeAlD
Ruxolitinib—PLK1—liver—type 2 diabetes mellitus	0.00145	0.00786	CbGeAlD
Ruxolitinib—TAOK2—adipose tissue—type 2 diabetes mellitus	0.00145	0.00786	CbGeAlD
Ruxolitinib—JAK1—cortex of kidney—type 2 diabetes mellitus	0.00143	0.00776	CbGeAlD
Ruxolitinib—CAMK1D—pancreas—type 2 diabetes mellitus	0.00143	0.00772	CbGeAlD
Ruxolitinib—HIPK2—cardiovascular system—type 2 diabetes mellitus	0.0014	0.0076	CbGeAlD
Ruxolitinib—TYK2—islet of Langerhans—type 2 diabetes mellitus	0.00137	0.00744	CbGeAlD
Ruxolitinib—HIPK2—kidney—type 2 diabetes mellitus	0.00137	0.00743	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Glimepiride—type 2 diabetes mellitus	0.00137	0.00621	CcSEcCtD
Ruxolitinib—Pancytopenia—Glipizide—type 2 diabetes mellitus	0.00137	0.00619	CcSEcCtD
Ruxolitinib—DAPK2—cortex of kidney—type 2 diabetes mellitus	0.00137	0.0074	CbGeAlD
Ruxolitinib—HIPK2—pancreas—type 2 diabetes mellitus	0.00136	0.00739	CbGeAlD
Ruxolitinib—MKNK2—islet of Langerhans—type 2 diabetes mellitus	0.00136	0.00735	CbGeAlD
Ruxolitinib—IRAK1—islet of Langerhans—type 2 diabetes mellitus	0.00136	0.00735	CbGeAlD
Ruxolitinib—DAPK3—cardiovascular system—type 2 diabetes mellitus	0.00135	0.0073	CbGeAlD
Ruxolitinib—NUAK2—nephron tubule—type 2 diabetes mellitus	0.00134	0.00724	CbGeAlD
Ruxolitinib—HIPK2—cortex of kidney—type 2 diabetes mellitus	0.00134	0.00724	CbGeAlD
Ruxolitinib—JAK3—adipose tissue—type 2 diabetes mellitus	0.00133	0.00722	CbGeAlD
Ruxolitinib—Thrombocytopenia—Tolbutamide—type 2 diabetes mellitus	0.00133	0.00601	CcSEcCtD
Ruxolitinib—JAK1—adipose tissue—type 2 diabetes mellitus	0.00133	0.00718	CbGeAlD
Ruxolitinib—DCLK1—adipose tissue—type 2 diabetes mellitus	0.00133	0.00718	CbGeAlD
Ruxolitinib—DAPK3—pancreas—type 2 diabetes mellitus	0.00131	0.0071	CbGeAlD
Ruxolitinib—Bone pain—Irbesartan—type 2 diabetes mellitus	0.00131	0.00592	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Miglitol—type 2 diabetes mellitus	0.0013	0.00589	CcSEcCtD
Ruxolitinib—ROCK1—cardiovascular system—type 2 diabetes mellitus	0.00129	0.00701	CbGeAlD
Ruxolitinib—CAMK1D—adipose tissue—type 2 diabetes mellitus	0.00129	0.00701	CbGeAlD
Ruxolitinib—PHKG2—adipose tissue—type 2 diabetes mellitus	0.00129	0.00696	CbGeAlD
Ruxolitinib—Pancytopenia—Glimepiride—type 2 diabetes mellitus	0.00128	0.00577	CcSEcCtD
Ruxolitinib—CLK2—cortex of kidney—type 2 diabetes mellitus	0.00127	0.00689	CbGeAlD
Ruxolitinib—ROCK1—kidney—type 2 diabetes mellitus	0.00127	0.00686	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Linagliptin—type 2 diabetes mellitus	0.00127	0.00573	CcSEcCtD
Ruxolitinib—DAPK2—adipose tissue—type 2 diabetes mellitus	0.00126	0.00685	CbGeAlD
Ruxolitinib—DYRK1A—cardiovascular system—type 2 diabetes mellitus	0.00126	0.00684	CbGeAlD
Ruxolitinib—BMPR2—cardiovascular system—type 2 diabetes mellitus	0.00126	0.00681	CbGeAlD
Ruxolitinib—Weight increased—Pioglitazone—type 2 diabetes mellitus	0.00126	0.00568	CcSEcCtD
Ruxolitinib—Weight decreased—Pioglitazone—type 2 diabetes mellitus	0.00125	0.00565	CcSEcCtD
Ruxolitinib—STK16—adipose tissue—type 2 diabetes mellitus	0.00124	0.00674	CbGeAlD
Ruxolitinib—HIPK2—adipose tissue—type 2 diabetes mellitus	0.00124	0.0067	CbGeAlD
Ruxolitinib—DYRK1A—kidney—type 2 diabetes mellitus	0.00124	0.00669	CbGeAlD
Ruxolitinib—BMPR2—kidney—type 2 diabetes mellitus	0.00123	0.00666	CbGeAlD
Ruxolitinib—Infestation—Pioglitazone—type 2 diabetes mellitus	0.00123	0.00557	CcSEcCtD
Ruxolitinib—Infestation NOS—Pioglitazone—type 2 diabetes mellitus	0.00123	0.00557	CcSEcCtD
Ruxolitinib—Weight increased—Glimepiride—type 2 diabetes mellitus	0.00122	0.00553	CcSEcCtD
Ruxolitinib—Weight increased—Sitagliptin—type 2 diabetes mellitus	0.00122	0.00552	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Glipizide—type 2 diabetes mellitus	0.00121	0.00549	CcSEcCtD
Ruxolitinib—Infection—Linagliptin—type 2 diabetes mellitus	0.00121	0.00549	CcSEcCtD
Ruxolitinib—Malnutrition—Repaglinide—type 2 diabetes mellitus	0.00121	0.00549	CcSEcCtD
Ruxolitinib—PLK3—liver—type 2 diabetes mellitus	0.00121	0.00656	CbGeAlD
Ruxolitinib—Thrombocytopenia—Tolazamide—type 2 diabetes mellitus	0.00121	0.00547	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Chlorpropamide—type 2 diabetes mellitus	0.00121	0.00547	CcSEcCtD
Ruxolitinib—BMPR2—cortex of kidney—type 2 diabetes mellitus	0.0012	0.00649	CbGeAlD
Ruxolitinib—MAP3K7—retina—type 2 diabetes mellitus	0.0012	0.00648	CbGeAlD
Ruxolitinib—Urinary tract infection—Pioglitazone—type 2 diabetes mellitus	0.0012	0.00541	CcSEcCtD
Ruxolitinib—Infestation—Sitagliptin—type 2 diabetes mellitus	0.00119	0.0054	CcSEcCtD
Ruxolitinib—Infestation NOS—Sitagliptin—type 2 diabetes mellitus	0.00119	0.0054	CcSEcCtD
Ruxolitinib—DAPK3—adipose tissue—type 2 diabetes mellitus	0.00119	0.00644	CbGeAlD
Ruxolitinib—Skin disorder—Linagliptin—type 2 diabetes mellitus	0.00119	0.00537	CcSEcCtD
Ruxolitinib—CLK2—adipose tissue—type 2 diabetes mellitus	0.00118	0.00638	CbGeAlD
Ruxolitinib—TYK2—retina—type 2 diabetes mellitus	0.00118	0.00636	CbGeAlD
Ruxolitinib—Haematuria—Pioglitazone—type 2 diabetes mellitus	0.00117	0.00531	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Tolbutamide—type 2 diabetes mellitus	0.00117	0.0053	CcSEcCtD
Ruxolitinib—NUAK2—pancreas—type 2 diabetes mellitus	0.00117	0.00632	CbGeAlD
Ruxolitinib—Thrombocytopenia—Acarbose—type 2 diabetes mellitus	0.00116	0.00525	CcSEcCtD
Ruxolitinib—Urinary tract infection—Sitagliptin—type 2 diabetes mellitus	0.00116	0.00525	CcSEcCtD
Ruxolitinib—MKNK2—retina—type 2 diabetes mellitus	0.00116	0.00628	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Gliclazide—type 2 diabetes mellitus	0.00115	0.00521	CcSEcCtD
Ruxolitinib—Malnutrition—Rosiglitazone—type 2 diabetes mellitus	0.00115	0.00519	CcSEcCtD
Ruxolitinib—NUAK2—cortex of kidney—type 2 diabetes mellitus	0.00115	0.0062	CbGeAlD
Ruxolitinib—MAP3K2—nephron tubule—type 2 diabetes mellitus	0.00114	0.00616	CbGeAlD
Ruxolitinib—CAMK1—liver—type 2 diabetes mellitus	0.00113	0.00614	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Sitagliptin—type 2 diabetes mellitus	0.00113	0.00511	CcSEcCtD
Ruxolitinib—CAMK2G—cardiovascular system—type 2 diabetes mellitus	0.00113	0.00609	CbGeAlD
Ruxolitinib—DYRK1A—adipose tissue—type 2 diabetes mellitus	0.00111	0.00603	CbGeAlD
Ruxolitinib—BMPR2—adipose tissue—type 2 diabetes mellitus	0.00111	0.006	CbGeAlD
Ruxolitinib—TYK2—nephron tubule—type 2 diabetes mellitus	0.00111	0.00599	CbGeAlD
Ruxolitinib—TAOK3—islet of Langerhans—type 2 diabetes mellitus	0.0011	0.00595	CbGeAlD
Ruxolitinib—CAMK2G—pancreas—type 2 diabetes mellitus	0.00109	0.00592	CbGeAlD
Ruxolitinib—IRAK1—nephron tubule—type 2 diabetes mellitus	0.00109	0.00591	CbGeAlD
Ruxolitinib—MKNK2—nephron tubule—type 2 diabetes mellitus	0.00109	0.00591	CbGeAlD
Ruxolitinib—LRRK2—kidney—type 2 diabetes mellitus	0.00109	0.00591	CbGeAlD
Ruxolitinib—CAMK2G—cortex of kidney—type 2 diabetes mellitus	0.00107	0.00581	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Chlorpropamide—type 2 diabetes mellitus	0.00107	0.00482	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Tolazamide—type 2 diabetes mellitus	0.00107	0.00482	CcSEcCtD
Ruxolitinib—Fatigue—Tolazamide—type 2 diabetes mellitus	0.00106	0.00482	CcSEcCtD
Ruxolitinib—LRRK2—cortex of kidney—type 2 diabetes mellitus	0.00106	0.00575	CbGeAlD
Ruxolitinib—NUAK2—adipose tissue—type 2 diabetes mellitus	0.00106	0.00574	CbGeAlD
Ruxolitinib—Anaemia—Rosiglitazone—type 2 diabetes mellitus	0.00106	0.00479	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Linagliptin—type 2 diabetes mellitus	0.00105	0.00477	CcSEcCtD
Ruxolitinib—Pancytopenia—Glyburide—type 2 diabetes mellitus	0.00105	0.00476	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Repaglinide—type 2 diabetes mellitus	0.00103	0.00464	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Acarbose—type 2 diabetes mellitus	0.00102	0.00463	CcSEcCtD
Ruxolitinib—TAOK2—liver—type 2 diabetes mellitus	0.00102	0.00551	CbGeAlD
Ruxolitinib—TYK2—cardiovascular system—type 2 diabetes mellitus	0.000994	0.00538	CbGeAlD
Ruxolitinib—BMP2K—adipose tissue—type 2 diabetes mellitus	0.000993	0.00537	CbGeAlD
Ruxolitinib—CAMK2G—adipose tissue—type 2 diabetes mellitus	0.000993	0.00537	CbGeAlD
Ruxolitinib—Flatulence—Glipizide—type 2 diabetes mellitus	0.000989	0.00447	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Nateglinide—type 2 diabetes mellitus	0.000987	0.00447	CcSEcCtD
Ruxolitinib—Fatigue—Nateglinide—type 2 diabetes mellitus	0.000986	0.00446	CcSEcCtD
Ruxolitinib—LRRK2—adipose tissue—type 2 diabetes mellitus	0.000984	0.00532	CbGeAlD
Ruxolitinib—MKNK2—cardiovascular system—type 2 diabetes mellitus	0.000981	0.00531	CbGeAlD
Ruxolitinib—TYK2—kidney—type 2 diabetes mellitus	0.000973	0.00527	CbGeAlD
Ruxolitinib—MAP3K3—nephron tubule—type 2 diabetes mellitus	0.000971	0.00525	CbGeAlD
Ruxolitinib—Thrombocytopenia—Repaglinide—type 2 diabetes mellitus	0.000969	0.00439	CcSEcCtD
Ruxolitinib—TYK2—pancreas—type 2 diabetes mellitus	0.000966	0.00523	CbGeAlD
Ruxolitinib—MAP3K7—cortex of kidney—type 2 diabetes mellitus	0.000965	0.00522	CbGeAlD
Ruxolitinib—Skin disorder—Repaglinide—type 2 diabetes mellitus	0.000962	0.00435	CcSEcCtD
Ruxolitinib—Malnutrition—Pioglitazone—type 2 diabetes mellitus	0.000961	0.00435	CcSEcCtD
Ruxolitinib—Pruritus—Tolbutamide—type 2 diabetes mellitus	0.00096	0.00434	CcSEcCtD
Ruxolitinib—MKNK2—pancreas—type 2 diabetes mellitus	0.000954	0.00516	CbGeAlD
Ruxolitinib—IRAK1—pancreas—type 2 diabetes mellitus	0.000954	0.00516	CbGeAlD
Ruxolitinib—Flatulence—Pioglitazone—type 2 diabetes mellitus	0.000947	0.00429	CcSEcCtD
Ruxolitinib—TYK2—cortex of kidney—type 2 diabetes mellitus	0.000947	0.00513	CbGeAlD
Ruxolitinib—Pancytopenia—Gliclazide—type 2 diabetes mellitus	0.000945	0.00428	CcSEcCtD
Ruxolitinib—TAOK3—retina—type 2 diabetes mellitus	0.00094	0.00509	CbGeAlD
Ruxolitinib—Malnutrition—Glimepiride—type 2 diabetes mellitus	0.000937	0.00424	CcSEcCtD
Ruxolitinib—RET—kidney—type 2 diabetes mellitus	0.000936	0.00507	CbGeAlD
Ruxolitinib—MKNK2—cortex of kidney—type 2 diabetes mellitus	0.000935	0.00506	CbGeAlD
Ruxolitinib—IRAK1—cortex of kidney—type 2 diabetes mellitus	0.000935	0.00506	CbGeAlD
Ruxolitinib—Malnutrition—Sitagliptin—type 2 diabetes mellitus	0.000934	0.00422	CcSEcCtD
Ruxolitinib—JAK1—liver—type 2 diabetes mellitus	0.00093	0.00503	CbGeAlD
Ruxolitinib—Infection—Rosiglitazone—type 2 diabetes mellitus	0.00093	0.00421	CcSEcCtD
Ruxolitinib—Flatulence—Sitagliptin—type 2 diabetes mellitus	0.00092	0.00416	CcSEcCtD
Ruxolitinib—Nervous system disorder—Rosiglitazone—type 2 diabetes mellitus	0.000918	0.00415	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Rosiglitazone—type 2 diabetes mellitus	0.000916	0.00414	CcSEcCtD
Ruxolitinib—CAMK1D—liver—type 2 diabetes mellitus	0.000908	0.00491	CbGeAlD
Ruxolitinib—Weight increased—Gliclazide—type 2 diabetes mellitus	0.000906	0.0041	CcSEcCtD
Ruxolitinib—JAK2—cardiovascular system—type 2 diabetes mellitus	0.000905	0.0049	CbGeAlD
Ruxolitinib—PHKG2—liver—type 2 diabetes mellitus	0.000902	0.00488	CbGeAlD
Ruxolitinib—MAP3K2—adipose tissue—type 2 diabetes mellitus	0.000901	0.00488	CbGeAlD
Ruxolitinib—MAP3K7—adipose tissue—type 2 diabetes mellitus	0.000893	0.00483	CbGeAlD
Ruxolitinib—Anaemia—Pioglitazone—type 2 diabetes mellitus	0.000889	0.00402	CcSEcCtD
Ruxolitinib—Asthenia—Tolazamide—type 2 diabetes mellitus	0.000886	0.00401	CcSEcCtD
Ruxolitinib—JAK2—kidney—type 2 diabetes mellitus	0.000885	0.00479	CbGeAlD
Ruxolitinib—TAOK3—nephron tubule—type 2 diabetes mellitus	0.000885	0.00479	CbGeAlD
Ruxolitinib—TYK2—adipose tissue—type 2 diabetes mellitus	0.000877	0.00475	CbGeAlD
Ruxolitinib—Pruritus—Tolazamide—type 2 diabetes mellitus	0.000874	0.00395	CcSEcCtD
Ruxolitinib—Pruritus—Chlorpropamide—type 2 diabetes mellitus	0.000874	0.00395	CcSEcCtD
Ruxolitinib—STK16—liver—type 2 diabetes mellitus	0.000873	0.00472	CbGeAlD
Ruxolitinib—MAP3K3—cardiovascular system—type 2 diabetes mellitus	0.000872	0.00472	CbGeAlD
Ruxolitinib—HIPK2—liver—type 2 diabetes mellitus	0.000868	0.0047	CbGeAlD
Ruxolitinib—Anaemia—Glimepiride—type 2 diabetes mellitus	0.000866	0.00392	CcSEcCtD
Ruxolitinib—IRAK1—adipose tissue—type 2 diabetes mellitus	0.000865	0.00468	CbGeAlD
Ruxolitinib—MKNK2—adipose tissue—type 2 diabetes mellitus	0.000865	0.00468	CbGeAlD
Ruxolitinib—Urinary tract infection—Gliclazide—type 2 diabetes mellitus	0.000863	0.0039	CcSEcCtD
Ruxolitinib—JAK2—cortex of kidney—type 2 diabetes mellitus	0.000862	0.00467	CbGeAlD
Ruxolitinib—Neutropenia—Valsartan—type 2 diabetes mellitus	0.000855	0.00387	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.000855	0.00387	CcSEcCtD
Ruxolitinib—Headache—Tolbutamide—type 2 diabetes mellitus	0.00085	0.00385	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Gliclazide—type 2 diabetes mellitus	0.000839	0.0038	CcSEcCtD
Ruxolitinib—Epistaxis—Gliclazide—type 2 diabetes mellitus	0.000837	0.00379	CcSEcCtD
Ruxolitinib—DAPK3—liver—type 2 diabetes mellitus	0.000834	0.00451	CbGeAlD
Ruxolitinib—MAP3K3—cortex of kidney—type 2 diabetes mellitus	0.000831	0.0045	CbGeAlD
Ruxolitinib—CLK2—liver—type 2 diabetes mellitus	0.000826	0.00447	CbGeAlD
Ruxolitinib—Asthenia—Nateglinide—type 2 diabetes mellitus	0.000821	0.00371	CcSEcCtD
Ruxolitinib—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.000816	0.00369	CcSEcCtD
Ruxolitinib—Dizziness—Tolazamide—type 2 diabetes mellitus	0.000816	0.00369	CcSEcCtD
Ruxolitinib—Infestation NOS—Valsartan—type 2 diabetes mellitus	0.000815	0.00369	CcSEcCtD
Ruxolitinib—Infestation—Valsartan—type 2 diabetes mellitus	0.000815	0.00369	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Pioglitazone—type 2 diabetes mellitus	0.000813	0.00368	CcSEcCtD
Ruxolitinib—Pruritus—Nateglinide—type 2 diabetes mellitus	0.000809	0.00366	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.000808	0.00365	CcSEcCtD
Ruxolitinib—Fatigue—Rosiglitazone—type 2 diabetes mellitus	0.000807	0.00365	CcSEcCtD
Ruxolitinib—Infestation NOS—Orlistat—type 2 diabetes mellitus	0.000806	0.00364	CcSEcCtD
Ruxolitinib—Infestation—Orlistat—type 2 diabetes mellitus	0.000806	0.00364	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Glipizide—type 2 diabetes mellitus	0.000802	0.00363	CcSEcCtD
Ruxolitinib—ROCK1—liver—type 2 diabetes mellitus	0.000801	0.00433	CbGeAlD
Ruxolitinib—JAK2—adipose tissue—type 2 diabetes mellitus	0.000798	0.00432	CbGeAlD
Ruxolitinib—TAOK3—cardiovascular system—type 2 diabetes mellitus	0.000795	0.0043	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Sitagliptin—type 2 diabetes mellitus	0.000789	0.00357	CcSEcCtD
Ruxolitinib—Urinary tract infection—Orlistat—type 2 diabetes mellitus	0.000783	0.00354	CcSEcCtD
Ruxolitinib—DYRK1A—liver—type 2 diabetes mellitus	0.000781	0.00423	CbGeAlD
Ruxolitinib—Infection—Pioglitazone—type 2 diabetes mellitus	0.00078	0.00353	CcSEcCtD
Ruxolitinib—Neutropenia—Metformin—type 2 diabetes mellitus	0.000779	0.00352	CcSEcCtD
Ruxolitinib—BMPR2—liver—type 2 diabetes mellitus	0.000778	0.00421	CbGeAlD
Ruxolitinib—TAOK3—kidney—type 2 diabetes mellitus	0.000778	0.00421	CbGeAlD
Ruxolitinib—Headache—Tolazamide—type 2 diabetes mellitus	0.000773	0.0035	CcSEcCtD
Ruxolitinib—Headache—Chlorpropamide—type 2 diabetes mellitus	0.000773	0.0035	CcSEcCtD
Ruxolitinib—TAOK3—pancreas—type 2 diabetes mellitus	0.000773	0.00418	CbGeAlD
Ruxolitinib—Malnutrition—Glyburide—type 2 diabetes mellitus	0.000772	0.00349	CcSEcCtD
Ruxolitinib—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.00077	0.00348	CcSEcCtD
Ruxolitinib—Epistaxis—Valsartan—type 2 diabetes mellitus	0.000769	0.00348	CcSEcCtD
Ruxolitinib—MAP3K3—adipose tissue—type 2 diabetes mellitus	0.000769	0.00416	CbGeAlD
Ruxolitinib—Headache—Linagliptin—type 2 diabetes mellitus	0.000765	0.00346	CcSEcCtD
Ruxolitinib—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.000762	0.00345	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Orlistat—type 2 diabetes mellitus	0.000762	0.00345	CcSEcCtD
Ruxolitinib—TAOK3—cortex of kidney—type 2 diabetes mellitus	0.000757	0.0041	CbGeAlD
Ruxolitinib—Infection—Sitagliptin—type 2 diabetes mellitus	0.000757	0.00342	CcSEcCtD
Ruxolitinib—Dizziness—Nateglinide—type 2 diabetes mellitus	0.000756	0.00342	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Glimepiride—type 2 diabetes mellitus	0.000748	0.00339	CcSEcCtD
Ruxolitinib—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.000747	0.00338	CcSEcCtD
Ruxolitinib—NUAK2—liver—type 2 diabetes mellitus	0.000743	0.00402	CbGeAlD
Ruxolitinib—Infestation—Metformin—type 2 diabetes mellitus	0.000743	0.00336	CcSEcCtD
Ruxolitinib—Infestation NOS—Metformin—type 2 diabetes mellitus	0.000743	0.00336	CcSEcCtD
Ruxolitinib—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.00074	0.00335	CcSEcCtD
Ruxolitinib—Haemoglobin—Valsartan—type 2 diabetes mellitus	0.000736	0.00333	CcSEcCtD
Ruxolitinib—Neutropenia—Irbesartan—type 2 diabetes mellitus	0.000735	0.00332	CcSEcCtD
Ruxolitinib—Haemorrhage—Valsartan—type 2 diabetes mellitus	0.000732	0.00331	CcSEcCtD
Ruxolitinib—Haemoglobin—Orlistat—type 2 diabetes mellitus	0.000727	0.00329	CcSEcCtD
Ruxolitinib—Haemorrhage—Orlistat—type 2 diabetes mellitus	0.000723	0.00327	CcSEcCtD
Ruxolitinib—Weight increased—Irbesartan—type 2 diabetes mellitus	0.000715	0.00324	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.000714	0.00323	CcSEcCtD
Ruxolitinib—Anaemia—Glyburide—type 2 diabetes mellitus	0.000714	0.00323	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.000707	0.0032	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Metformin—type 2 diabetes mellitus	0.000702	0.00318	CcSEcCtD
Ruxolitinib—TAOK3—adipose tissue—type 2 diabetes mellitus	0.000701	0.00379	CbGeAlD
Ruxolitinib—Pruritus—Repaglinide—type 2 diabetes mellitus	0.0007	0.00317	CcSEcCtD
Ruxolitinib—BMP2K—liver—type 2 diabetes mellitus	0.000696	0.00377	CbGeAlD
Ruxolitinib—CAMK2G—liver—type 2 diabetes mellitus	0.000696	0.00377	CbGeAlD
Ruxolitinib—Malnutrition—Gliclazide—type 2 diabetes mellitus	0.000694	0.00314	CcSEcCtD
Ruxolitinib—LRRK2—liver—type 2 diabetes mellitus	0.00069	0.00373	CbGeAlD
Ruxolitinib—Infection—Bromocriptine—type 2 diabetes mellitus	0.000685	0.0031	CcSEcCtD
Ruxolitinib—Flatulence—Gliclazide—type 2 diabetes mellitus	0.000683	0.00309	CcSEcCtD
Ruxolitinib—Urinary tract infection—Irbesartan—type 2 diabetes mellitus	0.000681	0.00308	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.000677	0.00306	CcSEcCtD
Ruxolitinib—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.000677	0.00306	CcSEcCtD
Ruxolitinib—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.000676	0.00306	CcSEcCtD
Ruxolitinib—Weight increased—Losartan—type 2 diabetes mellitus	0.000673	0.00305	CcSEcCtD
Ruxolitinib—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000671	0.00304	CcSEcCtD
Ruxolitinib—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.00067	0.00303	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Irbesartan—type 2 diabetes mellitus	0.000663	0.003	CcSEcCtD
Ruxolitinib—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.000662	0.00299	CcSEcCtD
Ruxolitinib—Epistaxis—Irbesartan—type 2 diabetes mellitus	0.000661	0.00299	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.00066	0.00299	CcSEcCtD
Ruxolitinib—Fatigue—Glimepiride—type 2 diabetes mellitus	0.000659	0.00298	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000658	0.00298	CcSEcCtD
Ruxolitinib—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.000657	0.00297	CcSEcCtD
Ruxolitinib—Anaemia—Gliclazide—type 2 diabetes mellitus	0.000641	0.0029	CcSEcCtD
Ruxolitinib—Urinary tract infection—Losartan—type 2 diabetes mellitus	0.000641	0.0029	CcSEcCtD
Ruxolitinib—Malnutrition—Valsartan—type 2 diabetes mellitus	0.000637	0.00288	CcSEcCtD
Ruxolitinib—MAP3K2—liver—type 2 diabetes mellitus	0.000632	0.00342	CbGeAlD
Ruxolitinib—Malnutrition—Orlistat—type 2 diabetes mellitus	0.00063	0.00285	CcSEcCtD
Ruxolitinib—Flatulence—Valsartan—type 2 diabetes mellitus	0.000628	0.00284	CcSEcCtD
Ruxolitinib—MAP3K7—liver—type 2 diabetes mellitus	0.000626	0.00339	CbGeAlD
Ruxolitinib—Epistaxis—Losartan—type 2 diabetes mellitus	0.000622	0.00281	CcSEcCtD
Ruxolitinib—Flatulence—Orlistat—type 2 diabetes mellitus	0.00062	0.00281	CcSEcCtD
Ruxolitinib—Headache—Repaglinide—type 2 diabetes mellitus	0.00062	0.00281	CcSEcCtD
Ruxolitinib—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000619	0.0028	CcSEcCtD
Ruxolitinib—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000618	0.0028	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Glyburide—type 2 diabetes mellitus	0.000617	0.00279	CcSEcCtD
Ruxolitinib—TYK2—liver—type 2 diabetes mellitus	0.000615	0.00333	CbGeAlD
Ruxolitinib—IRAK1—liver—type 2 diabetes mellitus	0.000607	0.00329	CbGeAlD
Ruxolitinib—MKNK2—liver—type 2 diabetes mellitus	0.000607	0.00329	CbGeAlD
Ruxolitinib—Pancytopenia—Ramipril—type 2 diabetes mellitus	0.000602	0.00272	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000595	0.00269	CcSEcCtD
Ruxolitinib—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000595	0.00269	CcSEcCtD
Ruxolitinib—Neutropenia—Ramipril—type 2 diabetes mellitus	0.000593	0.00268	CcSEcCtD
Ruxolitinib—Asthenia—Glipizide—type 2 diabetes mellitus	0.000588	0.00266	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000586	0.00265	CcSEcCtD
Ruxolitinib—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000586	0.00265	CcSEcCtD
Ruxolitinib—Malnutrition—Metformin—type 2 diabetes mellitus	0.00058	0.00263	CcSEcCtD
Ruxolitinib—Pruritus—Glipizide—type 2 diabetes mellitus	0.00058	0.00262	CcSEcCtD
Ruxolitinib—Weight increased—Ramipril—type 2 diabetes mellitus	0.000577	0.00261	CcSEcCtD
Ruxolitinib—Flatulence—Metformin—type 2 diabetes mellitus	0.000572	0.00259	CcSEcCtD
Ruxolitinib—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000563	0.00255	CcSEcCtD
Ruxolitinib—Infection—Gliclazide—type 2 diabetes mellitus	0.000562	0.00254	CcSEcCtD
Ruxolitinib—JAK2—liver—type 2 diabetes mellitus	0.000559	0.00303	CbGeAlD
Ruxolitinib—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000555	0.00251	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	0.000554	0.00251	CcSEcCtD
Ruxolitinib—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00055	0.00249	CcSEcCtD
Ruxolitinib—Urinary tract infection—Ramipril—type 2 diabetes mellitus	0.00055	0.00249	CcSEcCtD
Ruxolitinib—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000548	0.00248	CcSEcCtD
Ruxolitinib—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000548	0.00248	CcSEcCtD
Ruxolitinib—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000547	0.00247	CcSEcCtD
Ruxolitinib—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000545	0.00247	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000544	0.00246	CcSEcCtD
Ruxolitinib—Dizziness—Glipizide—type 2 diabetes mellitus	0.000542	0.00245	CcSEcCtD
Ruxolitinib—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000541	0.00245	CcSEcCtD
Ruxolitinib—Flatulence—Irbesartan—type 2 diabetes mellitus	0.00054	0.00244	CcSEcCtD
Ruxolitinib—MAP3K3—liver—type 2 diabetes mellitus	0.000539	0.00292	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000539	0.00244	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.000535	0.00242	CcSEcCtD
Ruxolitinib—Epistaxis—Ramipril—type 2 diabetes mellitus	0.000533	0.00241	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000532	0.00241	CcSEcCtD
Ruxolitinib—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000519	0.00235	CcSEcCtD
Ruxolitinib—Infection—Valsartan—type 2 diabetes mellitus	0.000517	0.00234	CcSEcCtD
Ruxolitinib—Headache—Glipizide—type 2 diabetes mellitus	0.000513	0.00232	CcSEcCtD
Ruxolitinib—Infection—Orlistat—type 2 diabetes mellitus	0.000511	0.00231	CcSEcCtD
Ruxolitinib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.00051	0.00231	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000509	0.0023	CcSEcCtD
Ruxolitinib—Flatulence—Losartan—type 2 diabetes mellitus	0.000508	0.0023	CcSEcCtD
Ruxolitinib—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000506	0.00229	CcSEcCtD
Ruxolitinib—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000505	0.00229	CcSEcCtD
Ruxolitinib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000505	0.00229	CcSEcCtD
Ruxolitinib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000504	0.00228	CcSEcCtD
Ruxolitinib—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000504	0.00228	CcSEcCtD
Ruxolitinib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000499	0.00226	CcSEcCtD
Ruxolitinib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000495	0.00224	CcSEcCtD
Ruxolitinib—Headache—Pioglitazone—type 2 diabetes mellitus	0.000492	0.00222	CcSEcCtD
Ruxolitinib—TAOK3—liver—type 2 diabetes mellitus	0.000492	0.00266	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000491	0.00222	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000489	0.00221	CcSEcCtD
Ruxolitinib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000488	0.00221	CcSEcCtD
Ruxolitinib—Headache—Glimepiride—type 2 diabetes mellitus	0.000479	0.00217	CcSEcCtD
Ruxolitinib—Headache—Sitagliptin—type 2 diabetes mellitus	0.000477	0.00216	CcSEcCtD
Ruxolitinib—Anaemia—Losartan—type 2 diabetes mellitus	0.000476	0.00215	CcSEcCtD
Ruxolitinib—Infection—Metformin—type 2 diabetes mellitus	0.00047	0.00213	CcSEcCtD
Ruxolitinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000464	0.0021	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000464	0.0021	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000463	0.00209	CcSEcCtD
Ruxolitinib—Skin disorder—Metformin—type 2 diabetes mellitus	0.00046	0.00208	CcSEcCtD
Ruxolitinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000456	0.00206	CcSEcCtD
Ruxolitinib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000452	0.00205	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000449	0.00203	CcSEcCtD
Ruxolitinib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000448	0.00203	CcSEcCtD
Ruxolitinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000447	0.00202	CcSEcCtD
Ruxolitinib—Pruritus—Glyburide—type 2 diabetes mellitus	0.000446	0.00202	CcSEcCtD
Ruxolitinib—Infection—Irbesartan—type 2 diabetes mellitus	0.000444	0.00201	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000444	0.00201	CcSEcCtD
Ruxolitinib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000443	0.002	CcSEcCtD
Ruxolitinib—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000442	0.002	CcSEcCtD
Ruxolitinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000438	0.00198	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000438	0.00198	CcSEcCtD
Ruxolitinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000434	0.00196	CcSEcCtD
Ruxolitinib—Headache—Bromocriptine—type 2 diabetes mellitus	0.000432	0.00195	CcSEcCtD
Ruxolitinib—Infection—Losartan—type 2 diabetes mellitus	0.000418	0.00189	CcSEcCtD
Ruxolitinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000412	0.00187	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000412	0.00186	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000409	0.00185	CcSEcCtD
Ruxolitinib—Fatigue—Metformin—type 2 diabetes mellitus	0.000408	0.00185	CcSEcCtD
Ruxolitinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000406	0.00184	CcSEcCtD
Ruxolitinib—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000406	0.00184	CcSEcCtD
Ruxolitinib—Pruritus—Gliclazide—type 2 diabetes mellitus	0.0004	0.00181	CcSEcCtD
Ruxolitinib—Headache—Glyburide—type 2 diabetes mellitus	0.000395	0.00179	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000386	0.00175	CcSEcCtD
Ruxolitinib—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000385	0.00174	CcSEcCtD
Ruxolitinib—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000374	0.00169	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000374	0.00169	CcSEcCtD
Ruxolitinib—Asthenia—Valsartan—type 2 diabetes mellitus	0.000373	0.00169	CcSEcCtD
Ruxolitinib—Asthenia—Orlistat—type 2 diabetes mellitus	0.000369	0.00167	CcSEcCtD
Ruxolitinib—Pruritus—Valsartan—type 2 diabetes mellitus	0.000368	0.00166	CcSEcCtD
Ruxolitinib—Pruritus—Orlistat—type 2 diabetes mellitus	0.000364	0.00164	CcSEcCtD
Ruxolitinib—Fatigue—Losartan—type 2 diabetes mellitus	0.000363	0.00164	CcSEcCtD
Ruxolitinib—Headache—Gliclazide—type 2 diabetes mellitus	0.000355	0.0016	CcSEcCtD
Ruxolitinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000354	0.0016	CcSEcCtD
Ruxolitinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000353	0.0016	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.000353	0.0016	CcSEcCtD
Ruxolitinib—Skin disorder—Ramipril—type 2 diabetes mellitus	0.00035	0.00158	CcSEcCtD
Ruxolitinib—Dizziness—Valsartan—type 2 diabetes mellitus	0.000344	0.00156	CcSEcCtD
Ruxolitinib—Dizziness—Orlistat—type 2 diabetes mellitus	0.00034	0.00154	CcSEcCtD
Ruxolitinib—Asthenia—Metformin—type 2 diabetes mellitus	0.00034	0.00154	CcSEcCtD
Ruxolitinib—Pruritus—Metformin—type 2 diabetes mellitus	0.000335	0.00152	CcSEcCtD
Ruxolitinib—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000332	0.0015	CcSEcCtD
Ruxolitinib—Headache—Valsartan—type 2 diabetes mellitus	0.000326	0.00147	CcSEcCtD
Ruxolitinib—Headache—Orlistat—type 2 diabetes mellitus	0.000322	0.00146	CcSEcCtD
Ruxolitinib—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000321	0.00145	CcSEcCtD
Ruxolitinib—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000316	0.00143	CcSEcCtD
Ruxolitinib—Dizziness—Metformin—type 2 diabetes mellitus	0.000313	0.00142	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000311	0.00141	CcSEcCtD
Ruxolitinib—Fatigue—Ramipril—type 2 diabetes mellitus	0.000311	0.00141	CcSEcCtD
Ruxolitinib—Asthenia—Losartan—type 2 diabetes mellitus	0.000302	0.00137	CcSEcCtD
Ruxolitinib—Pruritus—Losartan—type 2 diabetes mellitus	0.000298	0.00135	CcSEcCtD
Ruxolitinib—Headache—Metformin—type 2 diabetes mellitus	0.000297	0.00134	CcSEcCtD
Ruxolitinib—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000296	0.00134	CcSEcCtD
Ruxolitinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000285	0.00129	CcSEcCtD
Ruxolitinib—Headache—Irbesartan—type 2 diabetes mellitus	0.00028	0.00127	CcSEcCtD
Ruxolitinib—Dizziness—Losartan—type 2 diabetes mellitus	0.000278	0.00126	CcSEcCtD
Ruxolitinib—Headache—Losartan—type 2 diabetes mellitus	0.000263	0.00119	CcSEcCtD
Ruxolitinib—Asthenia—Ramipril—type 2 diabetes mellitus	0.000259	0.00117	CcSEcCtD
Ruxolitinib—Pruritus—Ramipril—type 2 diabetes mellitus	0.000255	0.00115	CcSEcCtD
Ruxolitinib—Dizziness—Ramipril—type 2 diabetes mellitus	0.000238	0.00108	CcSEcCtD
Ruxolitinib—CYP3A4—kidney—type 2 diabetes mellitus	0.000236	0.00128	CbGeAlD
Ruxolitinib—Headache—Ramipril—type 2 diabetes mellitus	0.000226	0.00102	CcSEcCtD
Ruxolitinib—CYP3A4—liver—type 2 diabetes mellitus	0.000149	0.000808	CbGeAlD
Ruxolitinib—JAK2—Disease—INS—type 2 diabetes mellitus	4.04e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.04e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NFKB1—type 2 diabetes mellitus	4.02e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.02e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.01e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—type 2 diabetes mellitus	4.01e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—type 2 diabetes mellitus	4e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—type 2 diabetes mellitus	3.98e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—type 2 diabetes mellitus	3.97e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.96e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LPL—type 2 diabetes mellitus	3.95e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	3.91e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	3.91e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT2—type 2 diabetes mellitus	3.91e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NFKB1—type 2 diabetes mellitus	3.9e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.9e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—type 2 diabetes mellitus	3.89e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—type 2 diabetes mellitus	3.88e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.87e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—SRC—type 2 diabetes mellitus	3.86e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—INS—type 2 diabetes mellitus	3.85e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3R1—type 2 diabetes mellitus	3.84e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SRC—type 2 diabetes mellitus	3.81e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	3.81e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.8e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.78e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.78e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.77e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—SRC—type 2 diabetes mellitus	3.75e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.74e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.74e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—INS—type 2 diabetes mellitus	3.73e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.72e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.72e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—type 2 diabetes mellitus	3.72e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.72e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.71e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SERPINE1—type 2 diabetes mellitus	3.71e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.71e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.7e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—type 2 diabetes mellitus	3.7e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.68e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.67e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—type 2 diabetes mellitus	3.67e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.64e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	3.64e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	3.64e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	3.64e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—SRC—type 2 diabetes mellitus	3.63e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INS—type 2 diabetes mellitus	3.62e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—RELA—type 2 diabetes mellitus	3.61e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.61e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.61e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.59e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.56e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.56e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—C3—type 2 diabetes mellitus	3.56e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—type 2 diabetes mellitus	3.54e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3R1—type 2 diabetes mellitus	3.54e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.53e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.52e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.5e-06	1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.5e-06	1e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.5e-06	1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	3.49e-06	9.97e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	3.49e-06	9.97e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.46e-06	9.91e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SRC—type 2 diabetes mellitus	3.46e-06	9.89e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.45e-06	9.87e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—type 2 diabetes mellitus	3.43e-06	9.81e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.43e-06	9.81e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—type 2 diabetes mellitus	3.42e-06	9.78e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.41e-06	9.75e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.39e-06	9.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.39e-06	9.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.38e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—type 2 diabetes mellitus	3.38e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AGT—type 2 diabetes mellitus	3.38e-06	9.67e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.37e-06	9.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.37e-06	9.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—type 2 diabetes mellitus	3.36e-06	9.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	3.36e-06	9.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	3.36e-06	9.6e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.34e-06	9.56e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.33e-06	9.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.32e-06	9.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—type 2 diabetes mellitus	3.31e-06	9.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—type 2 diabetes mellitus	3.31e-06	9.48e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	3.3e-06	9.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—type 2 diabetes mellitus	3.28e-06	9.39e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—type 2 diabetes mellitus	3.28e-06	9.39e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.28e-06	9.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.27e-06	9.37e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.27e-06	9.37e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.27e-06	9.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—type 2 diabetes mellitus	3.24e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	3.24e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	3.24e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	3.24e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.23e-06	9.23e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.2e-06	9.14e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—type 2 diabetes mellitus	3.18e-06	9.11e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.18e-06	9.08e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.18e-06	9.08e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.17e-06	9.08e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—type 2 diabetes mellitus	3.16e-06	9.03e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—type 2 diabetes mellitus	3.15e-06	9.02e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.14e-06	8.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.12e-06	8.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—type 2 diabetes mellitus	3.09e-06	8.84e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RELA—type 2 diabetes mellitus	3.08e-06	8.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NFKB1—type 2 diabetes mellitus	3.05e-06	8.72e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	3.05e-06	8.71e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—type 2 diabetes mellitus	3.04e-06	8.71e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—type 2 diabetes mellitus	3.03e-06	8.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—type 2 diabetes mellitus	3.03e-06	8.67e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RELA—type 2 diabetes mellitus	2.99e-06	8.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.95e-06	8.45e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.93e-06	8.39e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—type 2 diabetes mellitus	2.91e-06	8.33e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.88e-06	8.25e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.88e-06	8.23e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.86e-06	8.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	2.85e-06	8.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—type 2 diabetes mellitus	2.84e-06	8.12e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INS—type 2 diabetes mellitus	2.83e-06	8.09e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.83e-06	8.09e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.81e-06	8.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.78e-06	7.96e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.78e-06	7.95e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.76e-06	7.9e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	2.76e-06	7.88e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	2.76e-06	7.88e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	2.76e-06	7.88e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	2.76e-06	7.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.74e-06	7.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.74e-06	7.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.72e-06	7.79e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.71e-06	7.74e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.7e-06	7.71e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.68e-06	7.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	2.64e-06	7.56e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.63e-06	7.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—type 2 diabetes mellitus	2.62e-06	7.5e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—type 2 diabetes mellitus	2.6e-06	7.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.6e-06	7.44e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.6e-06	7.44e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—type 2 diabetes mellitus	2.57e-06	7.35e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.55e-06	7.29e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.55e-06	7.29e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—type 2 diabetes mellitus	2.52e-06	7.22e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.52e-06	7.21e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.49e-06	7.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—type 2 diabetes mellitus	2.49e-06	7.12e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.48e-06	7.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.48e-06	7.1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.46e-06	7.02e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—type 2 diabetes mellitus	2.45e-06	7e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.43e-06	6.95e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.42e-06	6.93e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—type 2 diabetes mellitus	2.4e-06	6.86e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.37e-06	6.78e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.36e-06	6.75e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—type 2 diabetes mellitus	2.35e-06	6.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—type 2 diabetes mellitus	2.34e-06	6.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RELA—type 2 diabetes mellitus	2.34e-06	6.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—type 2 diabetes mellitus	2.33e-06	6.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—type 2 diabetes mellitus	2.33e-06	6.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—type 2 diabetes mellitus	2.3e-06	6.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.29e-06	6.56e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.29e-06	6.55e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—type 2 diabetes mellitus	2.26e-06	6.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.25e-06	6.42e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.25e-06	6.42e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.23e-06	6.38e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.21e-06	6.32e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.2e-06	6.3e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.19e-06	6.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.19e-06	6.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.19e-06	6.26e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.19e-06	6.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.18e-06	6.22e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.17e-06	6.22e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.17e-06	6.19e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—type 2 diabetes mellitus	2.15e-06	6.15e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.14e-06	6.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.13e-06	6.08e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.12e-06	6.07e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.11e-06	6.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.11e-06	6.03e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.1e-06	6.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.09e-06	5.99e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.06e-06	5.89e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.04e-06	5.83e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.01e-06	5.74e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.99e-06	5.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.97e-06	5.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.96e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.96e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.96e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.93e-06	5.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.93e-06	5.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—type 2 diabetes mellitus	1.91e-06	5.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.91e-06	5.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.87e-06	5.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.84e-06	5.25e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.8e-06	5.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.79e-06	5.11e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.78e-06	5.08e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.78e-06	5.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—type 2 diabetes mellitus	1.77e-06	5.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—type 2 diabetes mellitus	1.76e-06	5.05e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.7e-06	4.87e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.7e-06	4.87e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.68e-06	4.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.64e-06	4.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.63e-06	4.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—type 2 diabetes mellitus	1.63e-06	4.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.61e-06	4.6e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—type 2 diabetes mellitus	1.58e-06	4.53e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.55e-06	4.44e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.51e-06	4.31e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.47e-06	4.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.47e-06	4.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.46e-06	4.18e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.46e-06	4.18e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.44e-06	4.12e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.4e-06	4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.36e-06	3.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.34e-06	3.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.31e-06	3.74e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.3e-06	3.73e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.27e-06	3.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.25e-06	3.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.24e-06	3.54e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.2e-06	3.44e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.18e-06	3.38e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.14e-06	3.27e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.14e-06	3.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.12e-06	3.21e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.12e-06	3.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.11e-06	3.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	9.75e-07	2.79e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	9.56e-07	2.74e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	8.77e-07	2.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	8.39e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	8.39e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	7.67e-07	2.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	3.86e-07	1.1e-06	CbGpPWpGaD
